The Food and Drug Administration (FDA) is holding a public meeting this spring to gain insight from people with autism and their families regarding new pharmaceutical treatments for the developmental condition.
“The public meeting is intended to allow FDA to obtain patient perspectives on the impact of autism on daily life as well as patient views on treatment approaches for autism,” the FDA said in a public notice.
Autism is one of 20 conditions the FDA aims to seek input on to better understand the impact diagnoses have on patients’ daily lives, the types of treatments that benefit patients most, and patients’ perspectives on the adequacy of available treatments.
FDA-approved treatments for those with autism spectrum disorder is limited. For example, antipsychotics such as Risperdal are approved to treat irritability in patients with autism. But the medication carries potentially devastating side effects, including gynecomastia, a condition in which adolescent boys grow female-like breasts. Many men who developed gynecomastia after taking Risperdal as boys have filed lawsuits against the manufacturer of the drug, Johnson & Johnson subsidiary Janssen Pharmaceuticals.
The FDA said that by soliciting feedback from those affected by autism, the agency hopes to gain a better understanding of how families select treatment options.
The public meeting is scheduled for May 4 at the FDA White Oak Campus in Silver Spring, Maryland, and will be live-streamed online. Public comments on the issue also will be solicited through July 5.
Source: Disability Scoop